

LIVER DISEASE TREATMENTS: THE GLOBAL MARKET



PHM057C
June 2015

Yogita Zutshi
Project Analyst

ISBN: 1-62296-100-5



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASON FOR DOING THIS STUDY	2
INTENDED AUDIENCE	2
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 EXECUTIVE SUMMARY	6
<i>SUMMARY TABLE GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, 2012-2019 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
THE LIVER	10
DEFINITIONS	10
FUNCTIONS OF LIVER	11
PRODUCTION OF BILE	11
STORAGE OF FATS, CARBOHYDRATES, PROTEINS, VITAMINS, AND MINERALS	11
REGULATION OF NECESSARY SUBSTANCES IN THE BLOOD	12
SYNTHESIS OF COAGULATING PROTEINS	12
REMOVAL OF HARMFUL SUBSTANCES	12
OTHER FUNCTIONS	13
COMMON SYMPTOMS OF LIVER DISEASE	13
FATIGUE	13
JAUNDICE	13
SWOLLEN ABDOMEN	13
EFFECTS OF HORMONAL IMBALANCE	14
STOOL ABNORMALITIES	14
POLYDYPسيا AND POLYURIA	14
HEPATIC ENCEPHALOPATHY	14
SEXUAL DYSFUNCTION	14
NON-SPECIFIC SYMPTOMS OF LIVER DISEASE	15
LIVER DISEASE	15
<i>TABLE 1 CLASSIFICATION OF LIVER DISEASE</i>	15
TOXIC INJURY TO THE LIVER	16
Drug-induced Liver Disease	16
Industrial and Environmental Toxins	16
Alcohol-induced	16
Postoperative Hepatic Dysfunction	17

TOPIC	PAGE NO.
INFECTIOUS AGENTS AND PARASITES	17
Hepatitis Virus	17
Hepatitis A	17
Hepatitis B	17
Hepatitis C	17
Hepatitis D	18
Hepatitis E	18
Neonatal Hepatitis	18
Bacterial and Other Pathogenic Agents	18
Parasites	19
IMMUNE DISORDERS	19
Autoimmune Hepatitis	19
Primary Biliary Cirrhosis	19
TUMORS	20
Primary Malignant Tumors	20
Metastatic Malignant Tumors	21
Benign Hepatic Tumors	21
Tumor-like Lesions	21
INHERITED LIVER DISEASES	21
Wilson's Disease	21
Alagille Syndrome	22
Hemochromatosis	22
Inborn Errors	23
Alpha-1 Antitrypsin Deficiency	23
Cysts	24
Galactosemia	24
Gilbert's Syndrome	24
Tyrosinemia	25
MISCELLANEOUS DISEASES AND CONDITIONS	25
Non-alcoholic Fatty Liver Disease	25
Biliary Atresia	26
Cirrhosis	27
Hepatic Encephalopathy	27
Variceal Bleeding	28
Fatty Liver Disease	29
Gallstones	30
Reye's Syndrome	30
Sarcoidosis	31
CHAPTER 4 CLASSIFICATION OF THERAPIES BY DISEASE AND PRODUCTS ON THE MARKET	33
VIRUS-INDUCED LIVER DISEASE AND HEPATITIS	33
VIRAL VACCINES	33
<i>TABLE 2 VACCINES FOR HEPATITIS A PREVENTION</i>	<i>33</i>
<i>TABLE 3 VACCINES FOR HEPATITIS B PREVENTION</i>	<i>33</i>
ANTIVIRAL DRUGS	34
Nucleoside Analogs	34
<i>TABLE 4 NUCLEOSIDE ANALOGS USED TO TREAT HEPATITIS</i>	<i>34</i>

TOPIC	PAGE NO.
Nucleotide Analogs	34
<i>TABLE 5 NUCLEOTIDE ANALOGS USED TO TREAT HEPATITIS</i>	35
Interferon	35
<i>TABLE 6 INTERFERONS USED TO TREAT HEPATITIS</i>	35
Protease Inhibitors	36
<i>TABLE 7 PROTEASE INHIBITORS USED TO TREAT HEPATITIS</i>	36
Immunoglobulins	36
<i>TABLE 8 IMMUNOGLOBULINS USED TO TREAT HEPATITIS</i>	36
LIVER TUMORS AND LIVER CANCER	37
CHEMOTHERAPEUTIC DRUGS	37
<i>TABLE 9 CHEMOTHERAPEUTIC DRUGS USED TO TREAT LIVER CANCER</i>	37
TARGETED THERAPY	38
<i>TABLE 10 TARGETED THERAPY USED TO TREAT LIVER CANCER</i>	38
CONGENITAL LIVER DEFECTS	38
AUTOIMMUNE LIVER DISEASES	38
<i>TABLE 11 DRUGS USED TO TREAT WILSON'S DISEASE</i>	39
CORTICOSTEROIDS	39
<i>TABLE 12 CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITIS</i>	39
IMMUNOSUPPRESSIVE AGENTS	40
<i>TABLE 13 IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS</i>	40
ANTIMETABOLITES	40
<i>TABLE 14 ANTIMETABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS</i>	40
ALCOHOL-INDUCED LIVER DISEASE	40
ANABOLIC STEROIDS	41
<i>TABLE 15 ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DISEASE</i>	41
ALCOHOL-ABUSE DRUGS	41
<i>TABLE 16 ALCOHOL-ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DISEASE</i>	41
CHRONIC LIVER DISEASE	41
ANTI-REJECTION MEDICATIONS	42
<i>TABLE 17 ANTI-REJECTION MEDICATIONS USED TO TREAT CHRONIC LIVER DISEASE</i>	42
ANTI-INFECTIVES	42
<i>TABLE 18 ANTI-INFECTIVES DRUGS USED TO TREAT CHRONIC LIVER DISEASE</i>	42
ANTIFUNGAL PROPHYLAXIS	43
<i>TABLE 19 ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS</i>	43
NON-ALCOHOLIC FATTY LIVER DISEASE	43
GALLSTONE-SOLUBILIZING AGENTS	44
<i>TABLE 20 GALLSTONE-SOLUBILIZING AGENTS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE</i>	44
OTHER DRUGS	44
<i>TABLE 21 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE</i>	44
CHAPTER 5 REGULATORY ASPECTS	46
<i>TABLE 22 NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013</i>	46
<i>TABLE 23 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013</i>	46
<i>FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013</i>	47

TOPIC	PAGE NO.
<i>TABLE 24 NEW DRUG APPLICATIONS, 2008-2013</i>	47
<i>TABLE 25 RECALLS, 2008-2014</i>	47
CHAPTER 6 PREVALENCE	50
U.S.	50
<i>TABLE 26 U.S. PREVALENCE OF LIVER DISEASE, 2000-2020 (NUMBER)</i>	51
<i>TABLE 27 U.S. HEPATITIS BURDEN, 2013 (NO. OF INFECTIONS)</i>	51
EUROPE	51
REST OF THE WORLD	52
CHAPTER 7 MARKET BY DISEASE TYPE	54
<i>TABLE 28 GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, THROUGH 2019 (\$ MILLIONS)</i>	54
<i>FIGURE 2 GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, 2012-2019 (\$ MILLIONS)</i>	54
HEPATITIS	55
<i>TABLE 29 GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	56
<i>FIGURE 3 GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, 2012-2019 (\$ MILLIONS)</i>	56
HEPATOCELLULAR CARCINOMA	56
<i>TABLE 30 GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	58
<i>FIGURE 4 GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, 2012-2019 (\$ MILLIONS)</i>	58
AUTOIMMUNE LIVER DISEASES	58
<i>TABLE 31 GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	59
<i>FIGURE 5 GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2012-2019 (\$ MILLIONS)</i>	59
ALCOHOL-INDUCED LIVER DISEASE	60
<i>TABLE 32 GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	61
<i>FIGURE 6 GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2012-2019 (\$ MILLIONS)</i>	61
CHRONIC LIVER DISEASE	61
<i>TABLE 33 GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	62
<i>FIGURE 7 GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, 2012-2019 (\$ MILLIONS)</i>	63
NON-ALCOHOLIC FATTY LIVER DISEASE	63
<i>TABLE 34 GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	64
<i>FIGURE 8 GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2012-2019 (\$ MILLIONS)</i>	65
CHAPTER 8 PIPELINE	67
<i>TABLE 35 CLINICAL TRIALS FOR LIVER DISEASES BY PHASE</i>	67
<i>TABLE 36 NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY PHASE</i>	71
<i>FIGURE 9 NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY PHASE</i>	71

TOPIC	PAGE NO.
CHAPTER 9 DRUG-INDUCED LIVER DISEASE	74
<i>TABLE 37 DRUGS THAT CAN CAUSE LIVER DISEASE</i>	76
MAJOR DRUGS THAT CAN CAUSE LIVER DISEASE	80
ACETAMINOPHEN (TYLENOL)	80
STATINS	80
NICOTINIC ACID (NIACIN)	80
AMIODARONE (CARDARONE)	80
NITROFURANTOIN	80
AUGMENTIN	80
CHAPTER 10 CURRENT SITUATION AND FUTURE PROSPECTS	82
PREVALENCE AND LIFE EXPECTANCY	82
LACK OF EDUCATION AND LIMITED TREATMENT OPTIONS	82
RESEARCH AND DEVELOPMENT	83
LIVER ORGANIZATIONS	84
CHAPTER 11 PATENT ANALYSIS	87
<i>TABLE 38 NUMBER OF U.S. PATENTS FOR DRUGS USED TO TREAT LIVER DISEASE BY COMPANY, 2012-NOVEMBER, 2014</i>	87
<i>TABLE 39 LIST OF PATENTS ISSUED, 2012-2014</i>	88
<i>TABLE 40 LIST OF PATENT APPLICATIONS, 2012-2014</i>	109
CHAPTER 12 COMPANY PROFILES	137
ABBOTT LABORATORIES	137
ACHILLION PHARMACEUTICALS	137
ACTAVIS INC.	138
ALKERMES	138
ANTIPODEAN PHARMACEUTICALS	139
BAYER HEALTHCARE PHARMACEUTICALS	139
BIOTEST	140
BRISTOL-MYERS SQUIBB	140
CONATUS PHARMACEUTICALS	141
ELI LILLY	141
GALECTIN THERAPEUTICS	142
GILEAD SCIENCES INC.	142
GLAXOSMITHKLINE	143
GLOBEIMMUNE	143
GRIFOLS INTERNATIONAL	144
INTERCEPT PHARMACEUTICALS	144
ISIS PHARMACEUTICALS	144
KYOWA HAKKO KIRIN	145
MERCK & CO.	145
NOVARTIS	146
OCERA THERAPEUTICS INC.	146
PEREGRINE	147
PFIZER	147
ROCHE	148

TOPIC	PAGE NO.
ROXANE LABORATORIES	148
SALIX PHARMACEUTICALS	149
SCHERING PLOUGH CORP.	149
TAKEDA PHARMACEUTICAL	150
VALEANT PHARMACEUTICALS	151
VERTEX PHARMACEUTICALS INC.	152
XIAMEN AMOYTOP BIOTECH	152
ZYDUS PHARMACEUTICALS INC.	153

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 CLASSIFICATION OF LIVER DISEASE	15
TABLE 2 VACCINES FOR HEPATITIS A PREVENTION	33
TABLE 3 VACCINES FOR HEPATITIS B PREVENTION	33
TABLE 4 NUCLEOSIDE ANALOGS USED TO TREAT HEPATITIS	34
TABLE 5 NUCLEOTIDE ANALOGS USED TO TREAT HEPATITIS	35
TABLE 6 INTERFERONS USED TO TREAT HEPATITIS	35
TABLE 7 PROTEASE INHIBITORS USED TO TREAT HEPATITIS	36
TABLE 8 IMMUNOGLOBULINS USED TO TREAT HEPATITIS	36
TABLE 9 CHEMOTHERAPEUTIC DRUGS USED TO TREAT LIVER CANCER	37
TABLE 10 TARGETED THERAPY USED TO TREAT LIVER CANCER	38
TABLE 11 DRUGS USED TO TREAT WILSON'S DISEASE	39
TABLE 12 CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITIS	39
TABLE 13 IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS	40
TABLE 14 ANTIMETABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS	40
TABLE 15 ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DISEASE	41
TABLE 16 ALCOHOL-ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DISEASE	41
TABLE 17 ANTI-REJECTION MEDICATIONS USED TO TREAT CHRONIC LIVER DISEASE	42
TABLE 18 ANTI-INFECTIVES DRUGS USED TO TREAT CHRONIC LIVER DISEASE	42
TABLE 19 ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS	43
TABLE 20 GALLSTONE-SOLUBILIZING AGENTS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE	44
TABLE 21 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE	44
TABLE 22 NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013	46
TABLE 23 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013	46
TABLE 24 NEW DRUG APPLICATIONS, 2008-2013	47
TABLE 25 RECALLS, 2008-2014	47
TABLE 26 U.S. PREVALENCE OF LIVER DISEASE, 2000-2020 (NUMBER)	51
TABLE 27 U.S. HEPATITIS BURDEN, 2013 (NO. OF INFECTIONS)	51
TABLE 28 GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, THROUGH 2019 (\$ MILLIONS)	54
TABLE 29 GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, THROUGH 2019 (\$ MILLIONS)	56
TABLE 30 GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, THROUGH 2019 (\$ MILLIONS)	58
TABLE 31 GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, THROUGH 2019 (\$ MILLIONS)	59
TABLE 32 GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, THROUGH 2019 (\$ MILLIONS)	61
TABLE 33 GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, THROUGH 2019 (\$ MILLIONS)	62
TABLE 34 GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, THROUGH 2019 (\$ MILLIONS)	64
TABLE 35 CLINICAL TRIALS FOR LIVER DISEASES BY PHASE	67
TABLE 36 NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY PHASE	71
TABLE 37 DRUGS THAT CAN CAUSE LIVER DISEASE	76

TABLE HEADING	PAGE NO.
TABLE 38 NUMBER OF U.S. PATENTS FOR DRUGS USED TO TREAT LIVER DISEASE BY COMPANY, 2012-NOVEMBER, 2014	87
TABLE 39 LIST OF PATENTS ISSUED, 2012-2014	88
TABLE 40 LIST OF PATENT APPLICATIONS, 2012-2014	109

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, 2012-2019 (\$ MILLIONS)	8
FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013	47
FIGURE 2 GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, 2012-2019 (\$ MILLIONS)	54
FIGURE 3 GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, 2012-2019 (\$ MILLIONS)	56
FIGURE 4 GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, 2012-2019 (\$ MILLIONS)	58
FIGURE 5 GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2012-2019 (\$ MILLIONS)	59
FIGURE 6 GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2012-2019 (\$ MILLIONS)	61
FIGURE 7 GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, 2012-2019 (\$ MILLIONS)	63
FIGURE 8 GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2012-2019 (\$ MILLIONS)	65
FIGURE 9 NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY PHASE	71